ISRCTN68126628已完成未知
Safety and efficacy of PROPranolol eye DROPs in newborns with retinopathy of prematurity (DROP-PROP)
A. Meyer University Children's Hospital (Italy)0 个研究点目标入组 55 人开始时间: 2014年3月27日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Preterm newborns (gestational age 23-32 weeks) with stage 2 ROP, zone II without plus
- •2. A signed parental informed consent
排除标准
- •1. Newborns with heart failure
- •2. Newborns with congenital cardiovascular anomalies, except for persistent ductus arteriosus, patent foramen ovale and small ventricular septal defects
- •3. Newborns with recurrent bradycardia (heart rate < 90 beat per minute)
- •4. Newborns with second or third degree atrioventricular block
- •5. Newborns with hypotension
- •6. Newborns with renal failure
- •7. Newborns with actual cerebral haemorrhage
- •8. Newborns with other diseases which contraindicate the use of beta-adrenoreceptor blockers
研究者
相似试验
进行中（未招募）
不适用
Safety and efficacy of propranolol eye drops in neonates with retinopathy of prematurity: a pilot study (DROP-ROP).The medical condition to be investigated is Retinopathy of Prematurity (ROP)EUCTR2013-002062-39-ITAzienda Ospedaliero-Universitaria Meyer
已完成
2 期
Safety and Efficacy of Propranolol Eye Drops in Treating Retinopathy of PrematureRetinopathy of PrematurityNCT02014454Azienda Ospedaliero, Universitaria Meyer23
进行中（未招募）
1 期
Safety and efficay of 0.2% propranolol eye drops in newborns with retinopathy of prematurityMedDRA version: 20.1Level: PTClassification code 10038933Term: Retinopathy of prematuritySystem Organ Class: 10015919 - Eye disordersRETINOPATHY OF PREMATURITYEUCTR2014-005472-29-ITAZIENDA OSPEDALIERO-UNIVERSITARIA MEYER96
已完成
2 期
Safety and Efficacy of Propranolol 0.2% Eye Drops in Treating Retinopathy of Premature: A Pilot Study (DROP-ROP-0.2%)Retinopathy of PrematurityNCT02504944Azienda Ospedaliero, Universitaria Meyer98
进行中（未招募）
不适用
Safety and efficacy of intravitreal injections of ranibizumab/Lucentis in combination with verteporfin photodynamic therapy (PDT) in patients with choroidal neovascularisation (CNV) secondary to age related macular degeneratioEUCTR2006-002977-33-SIniversity Eye Hospital10